Cybin Inc Revenue Growth Rates (CYBN), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Cybin Inc   (NYSEAMER: CYBN)
 

CYBN's Revenue Growth by Quarter and Year

Cybin Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

CYBN Revenue (in millions $) FY 2025 FY 2024 FY 2023 FY 2022
4th Quarter December 159.15
3rd Quarter September 0.00
2nd Quarter June 0.00
1st Quarter March 0.00
FY 159.15





CYBN Revenue fourth quarter 2025 Y/Y Growth Comment
Cybin Inc showed record Revenue surge in the fourth quarter 2025 with 123.74% from the fourth quarter 2025 2024, to $ 159.15 millions.
This represents worst decline in recent Company history.

Looking into fourth quarter 2025 results within Major Pharmaceutical Preparations industry 21 other companies have achieved higher Revenue growth. While Cybin Inc ' s Revenue doubling of 123.74% ranks overall at the positon no. 149 in the fourth quarter 2025.


CYBN Revenue ( Y/Y Growth %) 2025
 2024 2023 2022
4th Quarter December 123.74 % - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY   123.74 % - - -

Financial Statements
Cybin Inc 's fourth quarter 2025 Revenue $ 159.15 millions CYBN's Income Statement
Cybin Inc 's fourth quarter 2024 Revenue $ 71.13 millions Quarterly CYBN's Income Statement


CYBN Revenue (Quarter on Quarter Growth %)

 2025
 2024 2023 2022
4th Quarter December - - - -
3rd Quarter September - - - -
2nd Quarter June - - - -
1st Quarter March - - - -
FY (Year on Year)   123.74 % - - -


Back to CYBN Growth rate Comparisons >> Back to CYBN Growth rate Comparisons >>


Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #50
Overall #149

Revenue Y/Y Growth Statistics
High Average Low
123.74 % 123.74 % 123.74 %
 
Revenue fourth quarter 2025 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #22
Healthcare Sector #50
Overall #149
Revenue Y/Y Growth Statistics
High Average Low
123.74 % 123.74 % 123.74 %
 

Revenue by Quarter for the Fiscal Years 2022, 2023, 2024, 2025

Cybin Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYBN's IV. Quarter Q/Q Revenue Comment


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Revenue Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


CYBN's IV. Quarter Q/Q Revenue Comment


Cybin Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2025)		 12 Months Ending
(Mar 31 2024)		 12 Months Ending
(Mar 31 2023)		 12 Months Ending
 12 Months Ending
Cumulative Revenue 12 Months Ending $ 159.15 $ 71.13 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) 123.74 % - - - -
Year on Year Revenue Growth Overall Ranking # 119 # 119 # 119 # 119 # 119
Seqeuential Revenue Change (TTM) 123.74 % - - - -
Seq. Revenue Growth (TTM) Overall Ranking # 119 # # # #


Cumulative Revenue growth Comment
With 123.74% annual Revenue growth, Cybin Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2025.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 119.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 36
Overall # 114

Revenue TTM Y/Y Growth Statistics
High Average Low
123.74 %
 123.74 %
123.74 %
(Mar 31 2025)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 36
S&P 500 # 114
Cumulative Revenue growth Comment
With 123.74% annual Revenue growth, Cybin Inc would report a record annual Revenue surge if the fiscal year would end on Mar 31 2025.

In the Healthcare sector 35 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from to 119.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 18
Healthcare Sector # 36
Overall # 114

Revenue TTM Y/Y Growth Statistics
High Average Low
123.74 %
123.74 %
123.74 %
(Mar 31 2025)  


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 18
Sector # 36
S&P 500 # 114




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
CYBN's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Mar 31 2025 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2025
Madrigal Pharmaceuticals Inc 210.77%$ 210.766 millions
Biocryst Pharmaceuticals Inc 209.09%$ 209.087 millions
Prenetics Global Limited201.94%$ 201.941 millions
Prokidney Corp 196.05%$ 196.053 millions
Mesoblast Limited191.39%$ 191.393 millions
Northwest Biotherapeutics Inc190.91%$ 190.909 millions
Zevra Therapeutics Inc 183.36%$ 183.360 millions
Spero Therapeutics Inc 174.51%$ 174.508 millions
Taysha Gene Therapies Inc 171.27%$ 171.266 millions
Compugen Ltd161.14%$ 161.140 millions
Nyxoah Sa156.29%$ 156.287 millions
Nuo Therapeutics Inc 153.57%$ 153.570 millions
Anaptysbio Inc 151.08%$ 151.082 millions
Theravance Biopharma inc 144.70%$ 144.700 millions
Voyager Therapeutics Inc 144.28%$ 144.282 millions
Esperion Therapeutics Inc 143.73%$ 143.725 millions
Foxo Technologies Inc 141.54%$ 141.542 millions
Volitionrx Limited133.25%$ 133.247 millions
Lineage Cell Therapeutics Inc 130.40%$ 130.404 millions
Tarsus Pharmaceuticals Inc 128.39%$ 128.388 millions
Evaxion A125.12%$ 125.120 millions
Cybin Inc 123.74%$ 123.742 millions
Elite Pharmaceuticals Inc 119.23%$ 119.225 millions
Pavmed Inc 116.67%$ 116.667 millions
Macrogenics Inc 113.03%$ 113.032 millions
C4 Therapeutics Inc 112.79%$ 112.787 millions
Vyne Therapeutics Inc 111.90%$ 111.905 millions
Tonix Pharmaceuticals Holding Corp 108.75%$ 108.753 millions
Phathom Pharmaceuticals Inc 94.12%$ 94.121 millions
Tenon Medical Inc 92.34%$ 92.338 millions


About Cybin Inc Revenue Growth Rates (CYBN), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Cybin Inc (CIK 1833141).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001833141-26-000046
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Cybin Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.